Stay updated on Bispecific Antibody MCLA-158 Clinical Trial
Sign up to get notified when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.

Latest updates to the Bispecific Antibody MCLA-158 Clinical Trial page
- Check3 days agoChange DetectedThe page version updated from v3.0.1 to v3.0.2, indicating a minor release. The 'Back to Top' navigation element was removed.SummaryDifference0.1%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%
- Check17 days agoChange DetectedThe web page has undergone significant updates, including the addition of specific drug information for Pembrolizumab and detailed resources related to various gastrointestinal diseases, while also removing some location-related terms and previous drug classifications.SummaryDifference3%
- Check24 days agoChange DetectedThere are no significant changes to the web page content.SummaryDifference0.1%
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check39 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11, indicating a revision in the content.SummaryDifference0.0%
Stay in the know with updates to Bispecific Antibody MCLA-158 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.